Venture capital for
Life Sciences

Founded in 2011,
venBio’s venture funds comprise nearly
Companies
that Matter
We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes intellectual property (IP), chemistry, manufacturing (CMC), and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.

Our mission
Latest news
Jun 2, 2025
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Read moreMay 16, 2025
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Read moreMay 9, 2025
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Read more